mTOR, a Potential Target to Treat Autism Spectrum Disorder
Open accessThe DOI matches its Crossref record; 39 of the 39 references it cites were found in a registry or an index.
Abstract
Mammalian target of rapamycin (mTOR) is a key regulator in various cellular processes, including cell growth, gene expression, and synaptic functions. Autism spectrum disorder (ASD) is frequently accompanied by monogenic disorders, such as tuberous sclerosis complex, phosphatase and tensin homolog tumor hamartoma syndrome, neurofibromatosis 1, and fragile X syndrome, in which mTOR is hyperactive. Mutations in the genes involved in the mTOR-mediated signaling pathway have been identified in some cases of syndromic ASD. Evidences indicate a pathogenic role for hyperactive mTOR-mediated signaling in ASD associated with these monogenic disorders, and mTOR inhibitors are a potential pharmacotherapy for ASD. Abnormal synaptic transmission through metabotropic glutamate receptor 5 may underlie in a part of ASD associated with hyperactive mTOR-mediated signaling. In this review, the relationship between mTOR and ASD is discussed.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
mTOR Signaling in Growth Control and Disease
Laplante, M., & Sabatini, D. M. (2012) · Cell · doi:10.1016/j.cell.2012.03.017 · Cited by 8,509
Verkerk, A. J. M. H., Pieretti, M., Sutcliffe, J. S., Fu, Y.-H., Kuhl, D. P. A., Pizzuti, A., Reiner, O., Richards, S., Victoria, M. F., Zhang, F., et al. (1991) · Cell · doi:10.1016/0092-8674(91)90397-h · Cited by 3,481 · cited 1×
“Unlike other disorders mentioned in this review, the genetic defect in most FXS cases is abnormal elongation of CGG repeats in the 5′-untranslated region of fragile X mental retardation 1 (FMR1) gene [81].”
BackgroundSarbassov, D. D., Ali, S. M., Kim, D.-H., Guertin, D. A., Latek, R. R., Erdjument-Bromage, H., Tempst, P., & Sabatini, D. M. (2004) · Current Biology · doi:10.1016/j.cub.2004.06.054 · Cited by 2,665
Mental Health Surveillance Among Children — United States, 2013–2019
Bitsko, R. H., Claussen, A. H., Lichstein, J., Black, L. I., Jones, S. E., Danielson, M. L., Hoenig, J. M., Davis Jack, S. P., Brody, D. J., Gyawali, S., et al. (2022) · MMWR Supplements · doi:10.15585/mmwr.su7102a1 · Cited by 1,723
Identification of the Tuberous Sclerosis Gene TSC1 on Chromosome 9q34
Slegtenhorst, M. V., Hoogt, R. D., Hermans, C., Nellist, M., Janssen, B., Verhoef, S., Lindhout, D., Ouweland, A. V. D., Halley, D., Young, J., et al. (1997) · Science · doi:10.1126/science.277.5327.805 · Cited by 1,648 · cited 1×
“Later TSC1 [31] and TSC2 [32] were identified as the causative genes.”
BackgroundIdentification and characterization of the tuberous sclerosis gene on chromosome 16
(1993) · Cell · doi:10.1016/0092-8674(93)90618-z · Cited by 1,645
The mGluR theory of fragile X mental retardation
Bear, M. F., Huber, K. M., & Warren, S. T. (2004) · Trends in Neurosciences · doi:10.1016/j.tins.2004.04.009 · Cited by 1,580 · cited 1×
“An analysis of synaptic plasticity in Fmr1 KO mice revealed that LTD triggered by mGluR was enhanced, whereas NMDA-dependent LTD was normal [97], leading to the proposal of “mGluR theory of FXS” [98].”
ResultNorthrup, H., Krueger, D. A., Northrup, H., Krueger, D. A., Roberds, S., Smith, K., Sampson, J., Korf, B., Kwiatkowski, D. J., Mowat, D., et al. (2013) · Pediatric Neurology · doi:10.1016/j.pediatrneurol.2013.08.001 · Cited by 1,502
Unusual brain growth patterns in early life in patients with autistic disorder: An MRI study
Courchesne, E., Karns, C. M., Davis, H. R., Ziccardi, R., Carper, R. A., Tigue, Z. D., Chisum, H. J., Moses, P., Pierce, K., Lord, C., et al. (2001) · Neurology · doi:10.1212/wnl.57.2.245 · Cited by 1,487
Altered synaptic plasticity in a mouse model of fragile X mental retardation
Huber, K. M., Gallagher, S. M., Warren, S. T., & Bear, M. F. (2002) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.122205699 · Cited by 1,349 · cited 1×
“An analysis of synaptic plasticity in Fmr1 KO mice revealed that LTD triggered by mGluR was enhanced, whereas NMDA-dependent LTD was normal [97], leading to the proposal of “mGluR theory of FXS” [98].”
Result
Cited by
Translation deregulation in human disease
Tahmasebi, S., Khoutorsky, A., Mathews, M. B., & Sonenberg, N. (2018) · Nature Reviews Molecular Cell Biology · doi:10.1038/s41580-018-0034-x · Cited by 255
mTOR-Dependent Cell Proliferation in the Brain
Ryskalin, L., Lazzeri, G., Flaibani, M., Biagioni, F., Gambardella, S., Frati, A., & Fornai, F. (2017) · BioMed Research International · doi:10.1155/2017/7082696 · Cited by 86
The Gut-Immune-Brain Axis in Autism Spectrum Disorders; A Focus on Amino Acids
van Sadelhoff, J. H. J., Perez Pardo, P., Wu, J., Garssen, J., van Bergenhenegouwen, J., Hogenkamp, A., Hartog, A., & Kraneveld, A. D. (2019) · Frontiers in Endocrinology · doi:10.3389/fendo.2019.00247 · Cited by 71
“Alterations in AA availability may lead to changes in signaling pathways that are sensitive to AAs, including the mTOR signaling and inflammatory pathways (77, 165).”
BackgroundD’Incal, C., Broos, J., Torfs, T., Kooy, R. F., & Vanden Berghe, W. (2022) · Cells · doi:10.3390/cells11081325 · Cited by 29
Gąssowska-Dobrowolska, M., Czapski, G. A., Cieślik, M., Zajdel, K., Frontczak-Baniewicz, M., Babiec, L., & Adamczyk, A. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms24087303 · Cited by 10
Metadata
- Authors
- Sato, A.
- Venue
- CNS & Neurological Disorders - Drug Targets
- Publisher
- Bentham Science Publishers Ltd.
- Published
- 2016-05-05
- Volume
- 15
- Issue
- 5
- Pages
- 533-543
- ISSN
- 1568-007X (ISSN-L)
- 1871-5273
- OpenAlex
- W2340623533
- Cited by
- 113
- References
- 39
- FWCI
- 8.32
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: mTOR, a Potential Target to Treat Autism Spectrum Disorder. https://app.cochat.ai/papers/10.2174/1871527315666160413120638
- The paper
- Sato, A. (2016). mTOR, a Potential Target to Treat Autism Spectrum Disorder. CNS & Neurological Disorders - Drug Targets. https://doi.org/10.2174/1871527315666160413120638
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.